ReviewInternational journal of molecular sciences2021
CD39 Regulation and Functions in T Cells.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 1 synthesis or guideline pooled it, 179 citations in OpenAlex.
- Tumour-infiltrating lymphocytes: from prognosis to treatment selection.British journal of cancer · 2023Pooled it
- The Biologic IRL201805 Alters Immune Tolerance Leading to Prolonged Pharmacodynamics and Efficacy in Rheumatoid Arthritis Patients.International journal of molecular sciences · 2024Trial
- Augmenting CAR T cell functionality and metabolism through CD39 downtuning.Molecular therapy. Oncology · 2026Article
- Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases.Signal transduction and targeted therapy · 2026Review
- Integrated epigenetic and genetic programming of primary human T cells.Nature biotechnology · 2026Article
- Single-nucleus RNA sequencing illuminates a functional analog of lymphoid organ in crustacean.Journal of advanced research · 2026Article
- [Causal associations between immune cell phenotypes and Ménière's disease: a bidirectional two-sample Mendelian randomization study and validation in mice].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Ectonucleotidases CD39 and CD73 expression levels are independent and inverse predictors of survival in muscle-invasive bladder cancer.The journal of pathology. Clinical research · 2026Article
- Precision medicine for G-CSF in ACLF: the biomarker gap.Hepatology international · 2026Article
- Nucleotide-Derived Competitive Inhibitors of Ectonucleotidase CD39─A Promising Extracellular Target for Immunotherapy of Cancer.Journal of medicinal chemistry · 2026Article
- CD8Nature reviews. Cardiology · 2026Review
- Genetically determined causality between immune cells and anxiety disorders: A Mendelian randomization study.Medicine · 2026Article
- Peripheral Regulatory T Cells Display Dynamic Memory Subset Frequency and Inhibitory Marker Expression Across Pregnancy.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Article
- Altered expression of the CD26/ADA axis in immune-mediated inflammation of infectious mononucleosis.Scientific reports · 2026Article
- Resistance exercise exerts anti-hypertensive effects and downregulates NTPDase/CD39 and ecto-5'-nucleotidase/CD73 expression in patients with chronic kidney disease undergoing hemodialysis.Purinergic signalling · 2026Article
- Single-cell and multi-omic characterization of ex vivo expanded ASTRLs from stable kidney transplant recipients reveals a regulatory T cell phenotype.Scientific reports · 2026Article
- Circulating T-lymphocyte subsets as biomarkers for immune checkpoint inhibitors in solid tumors.Clinical and experimental immunology · 2026Review
- The Relationship Between Immune Cells and Uterine Fibroids: A Bidirectional Mendelian Randomization Study.International journal of women's health · 2026Article
- Multifaceted mechanistic exploration ofFrontiers in cell and developmental biology · 2026Article
- CD39 in the pathogenesis of neuro-Behçet disease: is it an immune regulator marker?Frontiers in immunology · 2026Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD39 is an enzyme which is responsible, together with CD73, for a cascade converting adenosine triphosphate into adenosine diphosphate and cyclic adenosine monophosphate, ultimately leading to the release of an immunosuppressive form of adenosine in the tumor microenvironment. Here, we first review the environmental and genetic factors shaping CD39 expression. Second, we report CD39 functions in the T cell compartment, highlighting its role in regulatory T cells, conventional CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.